These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1574011)

  • 1. Increased fibrinolytic potential induced by gliclazide in type I and type II diabetic patients.
    Gram J; Jespersen J
    Metabolism; 1992 May; 41(5 Suppl 1):25-9. PubMed ID: 1574011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Macroangiopathy and type 2 diabetes mellitus: significance of Diamicron].
    Lesobre B
    Journ Annu Diabetol Hotel Dieu; 1990; ():325-34. PubMed ID: 2195215
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemobiological properties of gliclazide.
    Ziegler O; Drouin P
    J Diabetes Complications; 1994; 8(4):235-9. PubMed ID: 7833500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients.
    Gram J; Jespersen J
    Am J Med; 1991 Jun; 90(6A):62S-66S. PubMed ID: 1908183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
    Holmes B; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Apr; 27(4):301-27. PubMed ID: 6373223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction and possible role of fibrinolysis in diabetes mellitus.
    Gram J; Jespersen J
    Semin Thromb Hemost; 1991 Oct; 17(4):412-6. PubMed ID: 1803511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From hemobiology to vascular disease: a review of the potential of gliclazide to influence the pathogenesis of diabetic vascular disease.
    Jennings PE
    J Diabetes Complications; 1994; 8(4):226-30. PubMed ID: 7833498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular benefits of gliclazide beyond glycemic control.
    Jennings PE
    Metabolism; 2000 Oct; 49(10 Suppl 2):17-20. PubMed ID: 11078471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology of vascular disease in diabetes: effects of gliclazide.
    Colwell JA
    Am J Med; 1991 Jun; 90(6A):50S-54S. PubMed ID: 1872305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an oral antidiabetic drug on the fibrinolytic system of blood in insulin-treated diabetic patients.
    Gram J; Jespersen J; Kold A
    Metabolism; 1988 Oct; 37(10):937-43. PubMed ID: 3050364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Symposium on Diabetes, Vascular Risks, and Gliclazide (Diamicron). Washington, DC, June 28, 1991.
    Metabolism; 1992 May; 41(5 Suppl 1):1-45. PubMed ID: 1349419
    [No Abstract]   [Full Text] [Related]  

  • 12. [Gliclazide: review of metabolic and vascular action].
    Alberti KG
    Diabete Metab; 1994 Nov; 20(3 Pt 2):341-8. PubMed ID: 7828778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gliclazide: metabolic and vascular effects--a perspective.
    Alberti KG; Johnson AB; Taylor R
    Metabolism; 1992 May; 41(5 Suppl 1):40-5. PubMed ID: 1574015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoglycemic treatments and the fibrinolytic system in maturity-onset diabetes mellitus without thromboembolic manifestations.
    Gamba G; Grignani G; Biancardi M; De Marco R; Grassi M; Ferrari E
    Acta Diabetol Lat; 1983; 20(1):63-70. PubMed ID: 6858544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolysis and risk factors of atherosclerotic disease, with special emphasis on diabetes mellitus.
    Wilkens HJ; Back N
    Circ Shock; 1978; 5(2):125-43. PubMed ID: 352570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonylureas and platelet function.
    Klaff LJ; Kernoff L; Vinik AI; Jackson WP; Jacobs P
    Am J Med; 1981 Mar; 70(3):627-30. PubMed ID: 6782875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolytic activity and diabetes control--evidence for a relationship. A preliminary report.
    Gunnarsson R; Nyman D; Wålinder O; Ostman J
    Acta Med Scand Suppl; 1980; 639():23-4. PubMed ID: 6932810
    [No Abstract]   [Full Text] [Related]  

  • 18. Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease.
    Panahloo A; Yudkin JS
    Coron Artery Dis; 1996 Oct; 7(10):723-31. PubMed ID: 8970763
    [No Abstract]   [Full Text] [Related]  

  • 19. Fibrin(ogen) and diabetes mellitus: don't forget fibrinolysis.
    Morale M; De Negri F; Carmassi F
    Diabetologia; 1997 Jun; 40(6):735-7. PubMed ID: 9222656
    [No Abstract]   [Full Text] [Related]  

  • 20. [Control of atherosclerosis in diabetes mellitus].
    Quiroz Martínez A
    Arch Cardiol Mex; 2003; 73 Suppl 1():S125-7. PubMed ID: 12966662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.